providers offering compounded tirzepatide for online telehealth consultations Telehealth Weight Loss | GLP-1

[1] [2] This trial enrolled adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity the primary cohort was largely without type 2 diabetes and assessed multiple doses of retatrutide against placebo over 24 weeks, with an extension to 48 weeks

This creates a genuine paradox

10.1038/s42003-022-04380-y 38 LiaoT.ZhangS

However, the additional information provided by patients, healthcare providers, and others, including compounders does not demonstrate that Lilly will be unable to meet projected demand, especially when weighed against the Lilly-provided data, the letter reads